Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/8414
Title: | Treatment of myasthenia gravis by preventing acetylcholine receptor modulation | Authors: | Losen, M Martinez-Martinez, Pilar Phernambucq, M Schuurman, J Parren, PWWI DE BAETS, Marc |
Issue Date: | 2008 | Publisher: | BLACKWELL PUBLISHING | Source: | Kaminski, HJ & Barohn, RJ (Ed.) MYASTHENIA GRAVIS AND RELATED DISORDERS: 11TH INTERNATIONAL CONFERENCE. p. 174-179. | Series/Report: | ANNALS OF THE NEW YORK ACADEMY OF SCIENCES | Series/Report no.: | 1132 | Abstract: | Myasthenia gravis (MG) is an autoimmune disease caused by antibodies mainly directed to the acetylcholine receptor (AChR) of the neuromuscular junction. Induction of antigenic modulation and complement activation by such autoantibodies leads to ultrastructural damage of the postsynaptic membrane and loss of AChR and associated proteins. Reduction of antigenic modulation by increasing the expression of the receptor-associated anchor protein, rapsyn, or by functionally monovalent competing IgG4 anti-AChR antibodies was shown to prevent MG disease activity. We propose that preventing antigenic modulation can be used as a treatment strategy for MG. | Notes: | Univ Maastricht, Neuroimmunol Grp, Inst Mental Hlth & Neurosci,Dept Neurosci, Netherlands European Grad Sch Neuro EURON, Maastricht, NL-6229 ER Netherlands. Genmab, Utrecht, Netherlands. Hasselt Univ, Neuroimmunol Grp, Biomed Res Inst BIOMED, Diepenbeek, Belgium. | Keywords: | rapsyn, IgG4, antigenic modulation, complement | Document URI: | http://hdl.handle.net/1942/8414 | ISBN: | 978-1-57331-687-3 | DOI: | 10.1196/annals.1405.034 | ISI #: | 000257139900021 | Category: | C1 | Type: | Proceedings Paper | Validations: | ecoom 2009 |
Appears in Collections: | Research publications |
Show full item record
SCOPUSTM
Citations
21
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
19
checked on Oct 1, 2024
Page view(s)
120
checked on Nov 7, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.